| Ytd | -49.51% | |
| 1y | -53.80% |
| Open | 3.72 | Prev Close | 3.73 | Low | 3.48 | High | 3.80 | Mkt Cap | 31.23M |
| Vol | 260.70K | Avg Vol | 307.63K | EPS | -0.84 | P/E | N/A | Forward P/E | -1.38 |
| Beta | 1.82 | Short Ratio | 0.77 | Inst. Own | 4.65% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 06-16 | 50-d Avg | 3.52 | 200-d Avg | 4.95 | 1yr Est | 15.00 |
BCTX News
Cell-based immunotherapy program is designed to harness patients’ own immune systemsBria-MEL+ is a p
Cell-based immunotherapy program is designed to harness patients' own immune systems Bria-MEL+ is a
FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a
FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a
Sunnybrook’s Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins Br
PHILADELPHIA and VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutic
Bria-IMT is currently being evaluated in BriaCell’s pivotal Phase 3 study of Bria-IMT in combination
PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutic
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX:BCT) ("BriaCell" or the "Company&
PHILADELPHIA and VANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutic
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company&
PHILADELPHIA and VANCOUVER, British Columbia, June 25, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutic
BriaCell Therapeutics (NASDAQ:BCTX) reported quarterly losses of $(0.99) per share. This is a 93.96
PHILADELPHIA & VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics
Final Bria-IMT™ Phase 2 data show 55% >1 year and 27% >2-year survival in heavily pre-treated metast
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL, BCTXZ))) (TSX:BCT) ("BriaCell" or the "
PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company&
PHILADELPHIA and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company&
PHILADELPHIA and VANCOUVER, British Columbia, May 22, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics
BriaCell expands push in women's health, building on Phase 2 success in advanced metastatic brea
BriaCell expands push in women's health, building on Phase 2 success in advanced metastatic breast c
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company&
PHILADELPHIA and VANCOUVER, British Columbia, May 14, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics
Other recently activated sites include Indiana University Melvin and Bren Simon Comprehensive Cancer
PHILADELPHIA and VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL)) (TSX:BCT) ("BriaCell" or the "Company&
PHILADELPHIA and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics
PHILADELPHIA and VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics
FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinic
FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinic
PHILADELPHIA and VANCOUVER, British Columbia, April 27, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeuti
Bria-OTS+ platform provides early, potent and durable activation of innate and adaptive immunity in
PHILADELPHIA and VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeuti
Phase 3 clinical data in heavily pretreated metastatic breast cancer patients with prior failed ADC,
PHILADELPHIA and VANCOUVER, British Columbia, April 20, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeuti
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX:BCT) ("BriaCell" or the "Company&
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXL))) (TSX:BCT) ("BriaCell" or the "Company
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ, BCTXL))) (TSX:BCT) ("BriaCell"), a c
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ, BCTXL))) (TSX:BCT) ("BriaCell" or th
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX:BCT) ("BriaCell" or the
BriaCell Therapeutics stock surges with positive news of patient's complete resolution of lung m
